<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14829">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253448</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU1302</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-1302</secondary_id>
    <nct_id>NCT00253448</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme</brief_title>
  <official_title>Phase II Trial of Conventional Radiotherapy With Stereotactic Radiosurgery to High Risk Tumor Regions as Determined by Functional Imaging in Patients With Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and
      cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor
      cells. Giving stereotactic radiosurgery together with radiation therapy may kill more tumor
      cells.

      PURPOSE: This phase II trial is studying how well giving stereotactic radiosurgery together
      with radiation therapy works in treating patients with glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the feasibility and efficacy of stereotactic radiosurgery to high-risk tumor
           regions and conventional radiotherapy in patients with glioblastoma multiforme.

        -  Determine overall survival of patients treated with this regimen.

      Secondary

        -  Determine 6-month progression-free survival of patients treated with this regimen.

        -  Determine the absence of tumor growth and/or activity on conventional MR/MR
           spectroscopy imaging in patients treated with this regimen.

        -  Determine the frequency and severity of RTOG (Radiation Therapy Oncology Group) CNS
           toxic effects in patients treated with this regimen.

        -  Determine the neurologic function and quality of life of patients treated with this
           regimen.

      OUTLINE: This is a pilot study.

      Patients undergo stereotactic radiosurgery to high-risk areas of active tumor determined by
      MR-spectroscopy. No more than 2 weeks later, patients undergo conventional radiotherapy once
      daily, 5 days a week, for 6 weeks.

      Quality of life is assessed at baseline, weekly during radiotherapy, at 1 and 3 months after
      completion of radiotherapy, and then every 3 months for 2 years, every 6 months for 3 years,
      and annually thereafter.

      After completion of study treatment, patients are followed periodically for at least 5
      years.

      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival After Treatment</measure>
    <time_frame>Minimum of 5 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Followed every 3 months for 2 years, every 6 months for 3 years, and annually thereafter for at least 5 years</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
    <description>stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed grade IV malignant glioblastoma multiforme

               -  Diagnosis by surgical biopsy or resection within the past 5 weeks

          -  Post-operative diagnostic contrast-enhanced MRI scan with MR spectroscopy must be
             performed prior to initiating study treatment

               -  High-risk area of active tumor without margin by MR spectroscopy

                    -  Meets the following criteria for radiosurgery:

                         -  Maximum diameter â‰¤ 40 mm

                         -  Located &gt; 5 mm from the optic nerve or chiasm

                         -  Does not involve the brainstem

          -  No multifocal or recurrent malignant glioma

        PATIENT CHARACTERISTICS:

        Performance status

          -  Karnofsky 50-100%

        Life expectancy

          -  At least 3 months

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant

          -  Negative pregnancy test

        PRIOR CONCURRENT THERAPY:

        Chemotherapy

          -  At least 6 weeks since chemotherapy

          -  Concurrent chemotherapy allowed

        Endocrine therapy

          -  Concurrent steroids allowed, but at the smallest therapeutic dose possible

        Radiotherapy

          -  No prior in-field radiotherapy to the head and neck

        Surgery

          -  See Disease Characteristics

          -  Recovered from prior surgery or any post-operative complication

        Other

          -  Concurrent antiseizure medications allowed
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Einstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kettering Medical Center, Wright State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest General Health Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 25, 2011</lastchanged_date>
  <firstreceived_date>November 11, 2005</firstreceived_date>
  <firstreceived_results_date>June 29, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from 12/31/2002 to 5/8/2008 from medical clinic</recruitment_details>
      <pre_assignment_details>One patient was not eligible for unknown reason</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stereotactic Radiosurgery Plus Conventional Radiotherapy</title>
          <description>Single 15-24 Gy Gamma Knife radiosurgical treatment to MR-Spectroscopy active region followed by 60 Gy of conventionally fractionated radiotherapy (2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stereotactic Radiosurgery Plus Conventional Radiotherapy</title>
          <description>Single 15-24 Gy Gamma Knife radiosurgical treatment to MR-Spectroscopy active region followed by 60 Gy of conventionally fractionated radiotherapy (2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.9" spread="12.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival After Treatment</title>
        <description>Followed every 3 months for 2 years, every 6 months for 3 years, and annually thereafter for at least 5 years</description>
        <time_frame>Minimum of 5 years.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Radiosurgery Plus Conventional Radiotherapy</title>
            <description>Single 15-24 Gy Gamma Knife radiosurgical treatment to MR-Spectroscopy active region followed by 60 Gy of conventionally fractionated radiotherapy (2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival After Treatment</title>
            <description>Followed every 3 months for 2 years, every 6 months for 3 years, and annually thereafter for at least 5 years</description>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Entire Cohort</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.8" lower_limit="11" upper_limit="19.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTOG Glioma Recursive Partitioning Class 3 n=4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22" lower_limit="22" upper_limit="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTOG Glioma Recursive Partitioning Class 4 n=13</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.7" lower_limit="14.5" upper_limit="29.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTOG Glioma Recursive Partitioning Class 5 n=16</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.5" lower_limit="9.2" upper_limit="18.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RTOG Glioma Recursive Partitioning Class 6 n=2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.9" lower_limit="2.7" upper_limit="5.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patients receiving concurrent chemotherapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.8" lower_limit="14.2" upper_limit="29.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Patients who were not candidates for chemotherapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11" lower_limit="7.2" upper_limit="18.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stereotactic Radiosurgery Plus Conventional Radiotherapy</title>
          <description>Single 15-24 Gy Gamma Knife radiosurgical treatment to MR-Spectroscopy active region followed by 60 Gy of conventionally fractionated radiotherapy (2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CVA</sub_title>
                <description>Cerebrovascular Accident in a patient taking anticoagulant warfarin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Re-operation for radiation necrosis</sub_title>
                <description>Re-operation for neurological symptom progression secondary to radiation necrosis</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Investigator</name_or_title>
      <organization>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</organization>
      <phone>937-395-8646</phone>
      <email>douglas.einstein@khnetwork.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
